Supplementary information

Data-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration

Fedor Levin¹; Daniel Ferreira²; Catharina Lange^{3,4}; Martin Dyrba¹; Eric Westman^{2,5}; Ralph Buchert⁶; Stefan J.

Teipel^{1,7}; Michel J. Grothe^{1,8*}; for the Alzheimer's Disease Neuroimaging Initiative[†]

¹German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Rostock, Germany

²Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer

Research, Karolinska Institutet, Stockholm, Sweden

³Department of Nuclear Medicine, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität

Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

⁴German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany

⁵Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and

Neuroscience, King's College London, London, UK.

⁶Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center

Hamburg-Eppendorf, Hamburg, Germany

⁷Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany

⁸Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de

Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.

*Corresponding Author:

Michel J. Grothe; Email: mgrothe@us.es

Supplementary table 1 A/T/N profiles across AD and prodromal AD subtypes.

	AD group, limbic-	AD group, typical	AD group, cortical-	Prodromal AD	Prodromal AD	Prodromal AD
	predominant subtype	subtype	predominant subtype	group, no	group, limbic-	group, typical
				hypometabolism	predominant subtype	subtype
				subtype		
Available data	71	80	11	52	105	45
A+T-	2 (3%)	10 (12.5%)	0 (0%)	5 (10%)	15 (14%)	5 (11%)
A+T-N-	2 (3%)	10 (12.5%)	0 (0%)	5 (10%)	14 (13%)	5 (11%)
A+T-N+	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)
A+T+	69 (97%)	70 (87.5%)	11 (100%)	47 (90%)	90 (86%)	40 (89%)
A+T+N-	8 (11%)	7 (9%)	0 (0%)	11 (21%)	10 (10%)	7 (16%)
A+T+N+	61 (86%)	63 (79%)	11 (100%)	36 (69%)	80 (76%)	33 (73%)

Numbers represent participants in each subtype corresponding to specific A/T/N profiles. Percentages in parentheses represent share among participants in the given subtype who have available CSF data. The tau pathology biomarker "T" category was defined as a CSF p-tau level over 19.2 pg/ml; the neurodegeneration biomarker "N" category was defined as a CSF t-tau level over 242 pg/ml (1).

Supplementary table 2 Structures defined in the Harvard-Oxford atlas that were used to measure the composite cortical volume.

Cortical region	Harvard-Oxford structure names
Frontal	frontal pole
	middle frontal gyrus
	inferior frontal gyrus (pars triangularis)
	inferior frontal gyrus (pars opercularis)
Parietal	superior parietal lobule
	supramarginal gyrus (anterior division)
	supramarginal gyrus (posterior division)
	angular gyrus
Temporal	temporal pole
	superior temporal gyrus (anterior division)
	superior temporal gyrus (posterior division)
Occipital cortex	lateral occipital cortex (superior division)

Supplementary table 3 Hazard ratios for progression of subtypes of patients with prodromal AD to dementia.

	Model 1			Model 2		
Variable	Value	HR	z-statistic	Value	HR	z-statistic
Subtype	No hypometabolism subtype (reference)	1		No hypometabolism subtype	0.21***	-3.75
	Limbic- predominant subtype	4.82***	3.75	Limbic-predominant subtype (reference)	1	
	Typical subtype	5.99***	4.17	Typical subtype	1.24	0.75
Age		0.99	-0.66		0.99	-0.66
Gender		1.15	0.55		1.15	0.55
Education		1.06	1.25		1.06	1.25
Observations	200			200		
Number of events	71			71		

Hazard ratios are presented with z-statistics. * P < .05, ** P < .01, *** P < .001. Patients who did not progress to dementia within the observation period or did not have follow-up CDR scores were censored.

Supplementary table 4 Mixed effects regression models of longitudinal cognitive decline across subtypes in the prodromal AD group; "no hypometabolism" subtype as reference.

	•	ction composite	Executive fund	ction composite score	Visuospatial 1	function composite score	Language fund	ction composite score
	Estimate	t-statistic	Estimate	t-statistic	Estimate	t-statistic	Estimate	t-statistic
Intercept	-0.177	-0.276	3.663***	4.758	0.736	1.373	1.009	1.554
Age	-0.002	-0.297	-0.05***	-5.426	-0.014*	-2.092	-0.024**	-3.011
Gender	0.218*	2.261	-0.043	-0.37	-0.003	-0.04	0.019	0.193
Education	0.054**	3.298	0.039*	1.985	0.022	1.575	0.08***	4.79
Follow-up time, months	-0.004*	-2.209	-0.005*	-2.068	-0.002	-0.581	-0.005*	-2.058
Limbic-predominant	-0.478***	-3.91	-0.339*	-2.31	-0.027	-0.248	-0.388**	-3.137
subtype								
Typical subtype	-0.759***	-5.696	-0.533**	-3.333	-0.237	-1.941	-0.324*	-2.402
Follow-up time ×	-0.011***	-4.498	-0.009**	-2.903	-0.007*	-2.216	-0.009**	-2.762
limbic-predominant								
subtype								
Follow-up time × typical subtype	-0.012***	-3.875	-0.017***	-4.367	-0.015***	-3.532	-0.013**	-2.94

Unstandardized estimates are presented with t-statistics. * P < .05, ** P < .01, *** P < .001. For interactions between the follow-up time in months and subtype, the no hypometabolism subtype acts as a reference. Random intercepts and random slopes for participants are included to account for multiple measurements.

Supplementary table 5 Mixed effects regression models of longitudinal cognitive decline across subtypes in the prodromal AD group; "limbic-predominant" subtype as reference.

	Memory function composite		Executive func	tion composite score	Visuospatial	function composite score	Language function composite score	
	S	score						
	Estimate	t-statistic	Estimate	t-statistic	Estimate	t-statistic	Estimate	t-statistic
Intercept	-0.655	-0.966	3.324***	4.065	0.709	1.245	0.621	0.901
Age	-0.002	-0.297	-0.05***	-5.426	-0.014*	-2.092	-0.024**	-3.011
Gender	0.218*	2.261	-0.043	-0.37	-0.003	-0.04	0.019	0.193
Education	0.054**	3.298	0.039*	1.985	0.022	1.575	0.08***	4.79
Follow-up time, months	-0.015***	-10.047	-0.014***	-7.2	-0.009***	-4.209	-0.015***	-7.059
Typical subtype	-0.281*	-2.315	-0.194	-1.33	-0.21	-1.882	0.064	0.523
No hypometabolism	0.478***	3.91	0.339*	2.31	0.027	0.248	0.388**	3.137
subtype								
Follow-up time ×	-0.001	-0.331	-0.008*	-2.25	-0.008	-1.931	-0.003	-0.808
typical subtype								
Follow-up time × no	0.011***	4.498	0.009**	2.903	0.007*	2.216	0.009**	2.762
hypometabolism								
subtype								

Unstandardized estimates are presented with t-statistics. * P < .05, ** P < .01, *** P < .001. For interactions between the follow-up time in months and subtype, the limbic-predominant subtype acts as a reference. Random intercepts and random slopes for participants are included to account for multiple measurements

Supplementary table 6 Comparisons between AD subtypes with respect to the ratio of inferior to medial temporal metabolism assessed with FDG-PET.

	AD group, limbic-	AD group,	AD group,	P-value, Global	Pair-wise	Pair-wise comparisons	
	predominant (S1)	ominant (S1) typical (S2) cortical- comparison (S1,					
			predominant (S3)	S2 and S3)	S1 vs S2	S1 vs S3	S2 vs S3
Inferior/medial	1.30 (0.13)	1.21 (0.10)	1.11 (0.07)	< 0.001	< 0.001	< 0.001	0.009
temporal metabolism							

The ratio of inferior to medial temporal metabolism was calculated as the average signal in the inferior temporal gyrus (anterior and posterior parts) divided by the signal in the combined hippocampus and amygdala regions as defined in the Harvard-Oxford atlas.

Values are presented as means with standard deviation in parentheses. Subtypes were compared with post-hoc pairwise t-tests with FDR correction. S1 = limbic-predominant subtype; S2 = typical subtype; S3 = cortical-predominant subtype.

Supplementary table 7 Correlations between the HV:CTV ratio and cognitive measures in the AD and in the prodromal AD groups.

	AD group	Prodromal AD group
	HV:CTV ratio	HV:CTV ratio
ADNI-MEM	-0.140	0.125
ADNI-EF	-0.373***	-0.120
ADNI-DIFF	0.339***	0.244***
ADNI-VS	-0.276***	0.095
ADNI-Lan	-0.228**	-0.007
MMSE	-0.046	0.057

^{*} P < .05, ** P < .01, *** P < .001

HV:CTV ratio: ratio of hippocampal grey matter volume to cortical composite grey matter volume.

Supplementary table 8 Missing values (at baseline) for demographic, clinical and biomarker characteristics in the AD dementia and prodromal AD groups.


	CN group (n = 179)	AD group, limbic-	AD group, typical	AD group, cortical-	Prodromal AD	Prodromal AD	Prodromal AD
		predominant subtype	subtype $(n = 86)$	predominant subtype	group, no	group, limbic-	group, typical
		(n = 79)		(n = 12)	hypometabolism	predominant subtype	subtype $(n = 49)$
					subtype $(n = 57)$	(n = 108)	
	n missing	n missing	n missing	n missing	n missing	n missing	n missing
Demographics							
Age	0	0	0	0	0	0	0
Sex	0	0	0	0	0	0	0
Education	0	0	0	0	0	0	0
ApoE genotype							
ΑροΕ-ε4	3	2	2	0	0	1	1
Cognition							
MMSE	0	0	0	0	0	0	0
ADNI-MEM	0	0	0	0	0	0	0
ADNI-EF	0	0	0	0	0	0	0
ADNI-DIFF	0	0	0	0	0	0	0
ADNI-VS	0	0	0	0	0	0	0
ADNI-Lan	0	0	0	0	0	0	0
Biomarkers							
AV45-PET SUVR	0	22	25	1	0	0	0
CSF Aβ	21	8	6	1	5	3	4
CSF t-tau	21	8	6	1	5	3	4
CSF p-tau	22	8	6	1	5	3	4
HV, adjusted to the	0	1	2	0	0	0	0


TIV								
CTV, adjusted to the	e 0	1	2	0	0	0	0	
TIV								
HV:CTV ratio	0	1	2	0	0	0	0	
WMH	3	7	5	1	1	0	1	

Supplementary figure 1. Determination of optimal clustering cutoff by objective criteria.

Two different objective criteria were used for determining the optimal number of clusters in the hierarchical clustering analysis. Respective criteria are plotted as y-values, whereas x-values represent numbers of clusters.


A - Davies-Bouldin criterion. Lower values indicate better clustering solutions. B - Silhouette criterion. Higher values indicate better clustering solutions.






Supplementary figure 2. Hierarchical clustering dendrogram and hypometabolic FDG-PET patterns of resulting AD subtypes at higher cluster solutions.


- A Five-cluster hierarchical clustering solution. Compared to the three-cluster solution, here the "typical" subtype is split into three subdivisions, which show a similar temporo-parietal pattern of hypometabolism, but with different degrees of lateralization.
- B Six-cluster hierarchical clustering solution as produced by splitting the limbic-predominant cluster into two separate clusters suggested by the dendrogram structure (split depicted by the dashed line on the dendrogram). This step separates a patient subgroup with only minimal hypometabolism.





Supplementary figure 3. Comparisons of hypometabolic FDG-PET patterns of subtypes of patients with AD

Voxel-wise hypometabolic patterns of the three AD subtypes were compared to each other. FDG-PET scans were scaled to the pons reference signal prior to analysis, and age, gender, years of education and MMSE were used as covariates. Statistical parametric maps of the group differences were converted into Cohen's d effect size maps to allow for a better comparison of the patterns across the unevenly sized subgroups. Please note, that in this figure the scales for effect size maps range from -1.1 to -0.01, and from 0.01 to 1.1.











Typical < Cortical-predominant Typical > Cortical-predominant Effect size d





Supplementary figure 4. Hypometabolic FDG-PET patterns of subtypes of patients with prodromal AD with adjusted scale

Voxel-wise hypometabolic patterns of the four prodromal AD subtypes as compared to the healthy control group. FDG-PET scans were scaled to the pons reference signal prior to analysis, and age, gender, and years of education were used as covariates. Statistical parametric maps of the group differences were converted into Cohen's d effect size maps to allow for a better comparison of the patterns across the unevenly sized subgroups. Please note that in this Figure the patterns are displayed at the same Cohen's d scale as the hypometabolic patterns of the AD dementia subtypes illustrated in Fig. 1 of the main text (i.e. from 0.01 to 1.6).



References

1. Salvado G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suarez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11(1):27.